The beneficial antispasticity effect of botulinum toxin type A is maintained after repeated treatment cycles

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 75, Issue 11, 2004, Pages 1558-1561

  Bakheit, A M O ^a   Fedorova, N V ^b   Skoromets, A A ^c   Timerbaeva, S L ^d   Bhakta, B B ^e   Coxon, L ^f  

^a Mount Gould Hospital   (United Kingdom)

^b Russ Med Acad Adv Med Studs   (Russian Federation)

^c PAVLOV FIRST SAINT PETERSBURG STATE MEDICAL UNIVERSITY   (Russian Federation)

^d RESEARCH CENTER OF NEUROLOGY   (Russian Federation)

^e ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^f IPSEN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; BOTULINUM TOXIN A ANTIBODY; NEUTRALIZING ANTIBODY; SPASMOLYTIC AGENT; TOXIN ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY PRODUCTION; ARM MUSCLE; ARTICLE; BLEPHAROSPASM; BLOOD SAMPLING; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DYSPHAGIA; DYSTONIA; FATIGUE; FEMALE; FUNCTIONAL ASSESSMENT; HEMIFACIAL SPASM; HUMAN; INJECTION; INJECTION PAIN; JOINT MOBILITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE TONE; OPEN STUDY; OUTCOMES RESEARCH; PARAMETER; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCORING SYSTEM; SPASTICITY; STROKE;

ADULT; AGED; ANTIBODY FORMATION; ARM; BOTULINUM TOXIN TYPE A; CEREBROVASCULAR ACCIDENT; DISABILITY EVALUATION; FEMALE; HEMIPLEGIA; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; MUSCLE SPASTICITY; MUSCLE TONUS; NEUROLOGIC EXAMINATION; NEUROMUSCULAR AGENTS; PROSPECTIVE STUDIES; RECURRENCE; RETREATMENT; TREATMENT OUTCOME;

EID: 7244242242     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.2003.035139     Document Type: Article

References (20)

1. Mizrahi EM, Angel RW. Impairment of voluntary movement by spasticity. Ann Neurol 1979;5:494-5.
2. Simpson DM, Alexander DN, O'Brien CF, et al. Botulinum toxin type A in the treatment of upper extremity spasticity: a randomized, double-blind, placebo-controlled trial. Neurology 1996;46:1306-10.
3. Bakheit AMO, Thilmann AF, Ward AB, et al. A randomized, double-blind, placebo-controlled, dose-ranging study to compare the efficacy and safety of three doses of botulinum toxin type A (Dysport) with placebo in upper limb spasticity after stroke. Stroke 2000;31:2402-6.
4. Bhakta BB, Cozens JA, Chamberlain MA, et al. Impact of botulinum toxin type A on disability and carer burden due to arm spasticity after stroke: a randomised double blind placebo controlled trial. J Neurol Neurosurg Psychiat 2000;69:217-21.
5. Brashear A, Gordon MF, Elovic E, et al. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after stroke. N Engl J Med 2002;347:395-400.
6. Hyman N, Barnes M, Bhakta B, et al. Botulinum toxin (Dysport) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomised, double blind, placebo controlled, dose ranging study. J Neurol Neurosurg Psychiat 2000;68:707-12.
7. Koman AL, Mooney JF 3rd, Smith BP, et al. Botulinum toxin type A neuromuscular blockade in the treatment of lower extremity spasticity in cerebral palsy: a randomised, double-blind, placebo-controlled trial. J Pediatr Orthop 2000;20:108-15.
8. De Paiva A, Meunier FA, Molgo J, et al. Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synoptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci USA 1999;96:3200-5.
9. Zuber M, Sebald M, Bathien N, et al. Botulinum toxin antibodies in dystonic patients treated with type A botulinum toxin: frequency and significance. Neurology 1993;43:1715-18.
10. Siatkowski RM, Tyutyunikov A, Biglan AW, et al. Serum antibody production to botulinum A toxin. Ophthalmology 1993;43:1715-18.
11. Bohannon RW, Smith MB. Inter-rater reliability of a modified Ashworth Scale of muscle spasticity. Phys Therapy 1987;67:206-7.
12. Aho K, Harmsen P, Hatano S, et al. Cerebrovascular disease in the community: results of a WHO collaborative study. Bulletin of the World Health Organisation 1980;58:113-30.
13. Delagi EF, Perotto A, Iazzetti J, et al. Anatomic guide for the electromyographer. Second ed. Springfield, IL: Charles C Thomas Publishers, 1980.
14. Hatheway CH, Dang C. Immunogenicity of the neurotoxins of Clostridium botulinum. In: Jankovic J, Hallett M, eds. Therapy with botulinum toxin. New York: Marcel Dekker, 1994:93-107.
15. Therapeutic and Technology Assessment Subcommittee of the American Academy of Medicine. The clinical usefulness of botulinum toxin A in treating neurologic disorders. Neurology 1990;40:1332-6.
16. Berweck S, Graham HK, Heinen F. Spasticity in children. In: Moore AP, Naumann M, eds. Handbook of botulinum toxin treatment. Second ed. Oxford, UK: Blackwell Science, 2003:297.
17. International ethical guidelines for biomedical research involving human subjects. Council for International Organisations of Medical Sciences. Geneva, 2002.
18. Emanuel EJ, Miller FG. The ethics of placebo-controlled trials - a middle ground. N Eng J Med 2001;345:915-19.
19. Bakheit AMO, Badwan DAH, McLellan DL. The effectiveness of chemical neurolysis in the treatment of lower limb muscle spasticity. Clin Rehabil 1996;10:40-3.
20. Hanna PA, Jankovic J, Vincent A. Comparison of mouse bioassay and immunoprecipitation assay for botulinum toxin antibodies. J Neurol Neurosurg Psychiat 1999;66:612-16.